Pharmafile Logo

News and Press Releases

Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease

Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025

Vandria
info@vandria.com
Route de la Corniche 8 1066 Epalinges Switzerland

Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease

Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025

Redx Pharma
info@redxpharma.com
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK

Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Pharming Group NV
info@pharming.com
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands

CPHI Milan analysis ‘Lombardy the best location for pharma manufacturing in Europe’

Report predicts significant growth for Lombardy’s pharma industry in 2025 as event directly contributes more than €120m to region 3 October 2024 – Milan, Italy – The global pharma industry...

Category: Pharmaceutical
Posted: October 3, 2024

CPHI
5 Howick Place, London SW1P 1WG

PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease

Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay developed by RxCelerate to test small molecules predicted to bind candidate target. 18...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 18, 2024

PlaqueTec
info@plaquetec.com
Maia Building (B270) Babraham Research Campus Cambridge CB22 3AT

CPHI Annual Report 2024: CPHI Milan Report predicts BLA and Tides approvals will surpass small molecules within the next three years

Bio and Tides predicted to be the fastest growing modality for CDMOs over the next five years 12 September 2024 – Milan, Italy – Ahead of CPHI Milan – the...

Category: Pharmaceutical
Posted: September 12, 2024

CPHI
5 Howick Place, London SW1P 1WG

Mission Therapeutics awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J Fox Foundation (MJFF), after...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024

Mission Therapeutics
info@missiontherapeutics.com
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board 28 May 2024 -- Cambridgeshire, UK -- Exonate, a biotechnology company developing...

Category: Biotechnology, Pharmaceutical
Posted: May 28, 2024

Exonate
info@exonate.com
WTL Moorfield Rd Duxford Cambridgeshire CB22 4PS United Kingdom

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, Germany, researchers from the Mayo Clinic in Rochester, USA and HepaRegeniX HRX-215 proved to be safe and well...

Category: Biotechnology
Posted: March 15, 2024